Jounce Therapeutics — Investor Presentation (January 2021)
26 slides from Jounce Therapeutics's investor presentation, Jan 11, 2021
Slide 1: Jounce Therapeutics: A Next Gen Immunotherapy Company
Jounce Therapeutics A Next Gen Immunotherapy Company January 2021
Slide 2: Legal Disclaimer
Legal Disclaimer Various statements concerning our future expectations, plans and prospects, including without limitation, our expectations regarding the timing, progress and results of discovery programs, preclinical studies and clinical trials for our product candidates and any future product cand
Slide 3: The Jounce Difference
The Jounce Difference 3 | © 2021 Jounce Therapeutics, Inc. Translational Science Platform – Proven Value Generation Platform Pipeline Corporate Profile Near-Term Milestones • Management team with proven track record in IO, oncology R&D and business development • Founded by IO pioneers with Nobel, Co
Slide 4: The Core of Our Approach: Translational Science Platform
The Core of Our Approach: Translational Science Platform Translational Drug Discovery • Sustainable engine • Multiple immune cell types • New IND every 12 – 18 months Reverse Translational Analysis • Patients with clinical outcomes • PD* and predictive biomarkers • Patients more likely to respond 4
Slide 5: IO Sensitive & IO Resistant Tumors: Significant But Different Opportunities
IO Sensitive & IO Resistant Tumors: Significant But Different Opportunities Green – T cells Green – T cells Red – Macrophages PD-(L)1i* Sensitive PD-(L)1i Resistant IO Market Growth *PD-(L)1i = PD-1 inhibitor or PD-L1 inhibitor **GlobalData Drug Sales and Consensus Forecast 2020 (GlobalData Inc.) Cu
Slide 6: Jounce Immunotherapy Pipeline
Not Disclosed Myeloid Not Disclosed Stroma Not Disclosed PD-(L)1i resistance mechanisms Jounce Immunotherapy Pipeline Program Target Biology Discovery Preclinical IND Enabling Clinical Phase 1 Phase 2 Phase 3 Vopratelimab ICOS CD4 T cell focused JTX-4014 PD-1 CD8 T cell focused JTX-8064 LILRB2 (ILT4
Slide 7: Recent News by Program
Recent News by Program 7 | © 2021 Jounce Therapeutics, Inc. POC Studies Underway JTX-8064 INNATE Study – IND accepted Nov 2020 – Sites open and patient screening began Dec 2020 Vopra SELECT Study – Biomarker selected patients began enrolling Oct 2020 JTX-4014: PD-1i Used in INNATE & SELECT Discovery
Slide 8: Lead Macrophage Program: JTX-8064
Lead Macrophage Program: JTX-8064
Slide 9: JTX-8064: Potential Macrophage Checkpoint Inhibitor
JTX-8064: Potential Macrophage Checkpoint Inhibitor • Novel, highly selective & potent IgG4 antibody to LILRB2 (ILT4) • Designed to reprogram tumor macrophages (M2 to M1) • Potential to reverse PD-(L)1i resistance JTX-8064 Antibody • IND acceptance Nov 2020; Sites open and patient screening began De
Slide 10: JTX-8064 Inhibits Macrophage Checkpoint LILRB2 (ILT4)
JTX-8064 Inhibits Macrophage Checkpoint LILRB2 (ILT4) 10 | © 2021 Jounce Therapeutics, Inc. Potential to Reverse PD-(L)1i Resistance Immunosuppressed Macrophage (M2) Immune Activated Macrophage (M1) Cytokine Production Antigen Presentation T-cell Activation
Slide 11: INNATE: JTX-8064 Mono and PD-1i Combo Dose Escalation and Expansion
INNATE: JTX-8064 Mono and PD-1i Combo Dose Escalation and Expansion 11 | © 2021 Jounce Therapeutics, Inc. • Designed to rapidly demonstrate POC • Indications selected based on: – Biology, RNA signatures and differentiated development opportunities – Unmet medical need: PD-(L)1i sensitive and resista
Slide 12: Opportunities Across Major IO Segments
• Potential to move to front line therapy in IO responsive tumor type • High unmet need due to minimal to no response to PD-(L)1i • Potential for rapid registration 12 | © 2021 Jounce Therapeutics, Inc. Opportunities Across Major IO Segments INNATE: Indication Selection & Unmet Need PD-(L)1i Naïve P
Slide 13: Vopratelimab & JTX-4014
Vopratelimab & JTX-4014
Slide 14: Vopratelimab Value Proposition
Vopratelimab Value Proposition • Highly durable clinical benefit and acceptable safety profile observed alone and in combination with PD-1i* or CTLA-4i • Vopra-specific PD biomarker – Treatment emergent peripheral ICOS hi CD4 T cells • Predictive biomarker – Tumor RNA signature (TISvopra) 14 | © 202
Slide 15: TISvopra Predicts for ICOS hi CD4 T Cells and Potential Clinical Benefit
TISvopra Predicts for ICOS hi CD4 T Cells and Potential Clinical Benefit ICONIC Overall Survival by ICOS hi CD4 Status* Treatment emergent ICOS hi CD4 T cells associated with improved survival TISvopra predicts for on treatment emergence of ICOS hi CD4 T cells and OS ICONIC Overall Survival by TISvo
Slide 16: TISvopra Selects for Potential Clinical Benefit From Both Vopra & PD-1i
TISvopra Selects for Potential Clinical Benefit From Both Vopra & PD-1i SELECT Study Population ~20% of Unselected NSCLC Population Unselected Population TISvopra 18 Gene Signature CD8 Related Biology (PD-1i) CD4 Related Biology (vopra) Archival Tumor Samples 16 | © 2021 Jounce Therapeutics, Inc.
Slide 17: SELECT: Phase 2 Predictive Biomarker Study
• IO naïve 2L NSCLC in ~75 patients selected with TISvopra • Powered to demonstrate statistical superiority of vopra + JTX-4014 versus JTX-4014 • Enrollment initiated October 2020, clinical data expected in late 2021 SELECT: Phase 2 Predictive Biomarker Study Clinical Study of Two Wholly Owned Antib
Slide 18: JTX-4014: PD-1 Inhibitor in Two POC Combination Studies
Data cut-off 30-OCT-2020 JTX-4014: PD-1 Inhibitor in Two POC Combination Studies Phase 1 Study Results* • 3/18 (16.7%) confirmed responses • No deaths or dose limiting toxicities Opportunities for JTX-4014 • Biomarker selected IO naïve patients (SELECT) • PD-(L)1i naïve & experienced patients (INNAT
Slide 19: Discovery
Discovery
Slide 20: Creating Value Through Discovery: Translational Science Platform
Creating Value Through Discovery: Translational Science Platform Novel & Sustainable Discovery • Right IO for right patients • Novel targets beyond T cells • Biomarker driven approach • New IND every 12 – 18 months Value Creation to Date • 3 wholly owned clinical programs • $360M in upfront business
Slide 21: JTX-1811: Selective Depletion of Tumor Infiltrating T Regulatory Cells
JTX-1811: Selective Depletion of Tumor Infiltrating T Regulatory Cells • Highly selective IgG1 monoclonal antibody to CCR8 • CCR8 is a chemokine receptor enriched on tumor infiltrating T-reg cells (T-regs) – T-regs cells are immunosuppressive in the TME • First in class mechanism designed for target
Slide 22: Gilead Licensed JTX-1811: Continued Value Generation
Gilead Licensed JTX-1811: Continued Value Generation 22 | © 2021 Jounce Therapeutics, Inc. • JTX-1811: Exclusively licensed to Gilead in October 2020 • $85M upfront license fee • $35M equity investment – ~14% ownership, 5.5M shares • Up to $685M in potential milestone payments – Up to $510M in devel
Slide 23: Milestones & Financials
Milestones & Financials
Slide 24: 2021 Milestones
2021 Milestones ▪ JTX-8064 (INNATE): ▪ Establish safety and RP2D ▪ Open tumor specific expansion cohorts ▪ Vopratelimab (SELECT): ▪ Complete trial enrollment (75 patients) ▪ Report preliminary efficacy data ▪ JTX-1811: ▪ IND acceptance ▪ Continue to advance multiple new targets through discovery pip
Slide 25: Financial Strength and Flexibility
Financial Strength and Flexibility NASDAQ: JNCE • Cash runway into 2023 • Ended 2020 with more than $200M (unaudited) – $105.3M cash and investments, as of September 30, 2020 – Additional $120M received in October 2020 25 | © 2021 Jounce Therapeutics, Inc. • ~39.9M shares as of November 2, 2020 Stro
Slide 26: Jounce Therapeutics: A Next Gen Immunotherapy Company
Jounce Therapeutics A Next Gen Immunotherapy Company
Jounce Therapeutics — Investor Presentation (January 2021) on 6ix